An integrated approach for deeper insight with both open and closed claims data
Pharma teams are under sharper financial scrutiny and policy pressure than they've been in years,...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen patches that is visible in RWD as demand for menopause support skyrockets. Menopause affects millions of women, yet it has long remained one of the...
Beyond reach: How real-world signals reshape healthcare audience targeting
Why most syndicated healthcare audiences fall short Claims data is the foundation of any credible...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen...
Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
MASH disease: From silent epidemic to treatment options
Liver disease is a growing global health concern, yet many of its most serious forms remain...
Why reliable mortality measurement in real-world evidence matters
Understanding mortality in taXonomy and the importance of post mortem activity This is the third...
Why underpowered studies are more dangerous than you think
In epidemiology, statistical power determines whether a study can accurately detect an effect of a...